Principal Investigator
LAWRENCE NEGRET
Enrollment Status
Not Accepting
Clinical Trial ID
Institutional Protocol #
20251053
Clinical Trial Summary
Randomized, Open-Label, Phase 3 Clinical Trial Of N-803 Plus Tislelizumab And Docetaxel Versus Docetaxel Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance To Immune Checkpoint Inhibitor Therapy
Phase
Phase III
Funding Agency/Sponsor
Industrial
Disease
Thoracic Oncology
Contact Information
Phone Number
305-243-2647